References
- LeRoy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001;28:1573–6.
- Lei W, Luo Y, Lei W, Luo Y, Yan K, Zhao S, Abnormal DNA methylation in CD4+ T cells from patients with systemic lupus erythematosus, systemic sclerosis, and dermatomyositis. Scand J Rheumatol 2009;38:369–74.
- Horikawa M, Hasegawa M, Komura K, Hayakawa I, Yanaba K, Matsushita T, Abnormal natural killer cell function in systemic sclerosis: altered cytokine production and defective killing activity. J Invest Dermatol 2005;125:731–7.
- Riccieri V, Parisi G, Spadaro A, Scrivo R, Barone F, Moretti T, Reduced circulating natural killer T cells and gamma/delta T cells in patients with systemic sclerosis. J Rheumatol 2005;32:283–6.
- Slobodin G, Ahmad MS, Rosner I, Peri R, Rozenbaum M, Kessel A, Regulatory T cells (CD4(+)CD25(bright)FoxP3(+)) expansion in systemic sclerosis correlates with disease activity and severity. Cell Immunol 2010;261:77–80.
- Banica L, Besliu A, Pistol G, Stavaru C, Ionescu R, Forsea AM, Quantification and molecular characterization of regulatory T cells in connective tissue diseases. Autoimmunity 2009;42:41–9.
- Murata M, Fujimoto M, Matsushita T, Hamaguchi Y, Hasegawa M, Takehara K, Clinical association of serum interleukin-17 levels in systemic sclerosis: is systemic sclerosis a Th17 disease? J Dermatol Sci 2008;50:240–2.
- Deleuran B, Abraham DJ. Possible implication of the effector CD4+ T-cell subpopulation TH17 in the pathogenesis of systemic scleroderma. Nat Clin Pract Rheumatol 2007;3:682–3.
- Sakkas LI, Platsoucas CD. Is systemic sclerosis an antigen-driven T cell disease? Arthritis Rheum 2004;50:1721–33.
- LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202–5.
- Szodoray P, Gal I, Barath S, Aleksza M, Horvath IF, Gergely P Jr, Immunological alterations in newly diagnosed primary Sjögren's syndrome characterized by skewed peripheral T-cell subsets and inflammatory cytokines. Scand J Rheumatol 2008;37:205–12.
- Szodoray P, Papp G, Horvath IF, Barath S, Sipka S, Nakken B, Cells with regulatory function of the innate and adaptive immune system in primary Sjögren's syndrome. Clin Exp Immunol 2009;157:343–9.
- Khanna D, Merkel PA. Outcome measures in systemic sclerosis: an update on instruments and current research. Curr Rheumatol Rep 2007;9:151–7.
- Needleman BW, Wigley FM, Stair RW. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor alpha, and interferon-gamma levels in sera from patients with scleroderma. Arthritis Rheum 1992;35:67–72.
- Suzuki J, Morimoto S, Amano H, Tokano Y, Takasaki Y, Hashimoto H. Serum levels of interleukin 15 in patients with rheumatic diseases. J Rheumatol 2001;28:2389–91.
- van Lieshout AW, Vonk MC, Bredie SJ, Joosten LB, Netea MG, van Riel PL, Enhanced interleukin-10 production by dendritic cells upon stimulation with Toll-like receptor 4 agonists in systemic sclerosis that is possibly implicated in CCL18 secretion. Scand J Rheumatol 2009;38:282–90.
- Hudson M, Walker JG, Fritzler M, Taillefer S, Baron M. Hypocomplementemia in systemic sclerosis – clinical and serological correlations. J Rheumatol 2007;34:2218–23.